Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.

@article{Jeryczynski2017PrefibroticearlyPM,
  title={Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.},
  author={Georg Jeryczynski and Juergen Michael Thiele and Bettina Gisslinger and Albert W{\"o}lfler and Martin Schalling and Andreas Gleiss and Sonja Burgstaller and Veronika Buxhofer-Ausch and Thamer Sliwa and Ernst Schloegl and Klaus Geissler and M Krauth and Alexander Nader and Michael Vesely and Ingrid Simonitsch-Klupp and Leonhard M{\"u}llauer and Christine Beham-Schmid and Heinz Gisslinger},
  journal={American journal of hematology},
  year={2017},
  volume={92 9},
  pages={885-891}
}
The 2016 revised WHO criteria for the diagnosis of pre-fibrotic/early primary myelofibrosis (pre-PMF) require at least one of the following four borderline expressed minor clinical criteria: anemia, leukocytosis, elevated lactate dehydrogenase and splenomegaly. In this study, we evaluated the relative frequency of these four criteria in a group of 170 pre-PMF patients and compared them to 225 ET cases. More than 91% of pre-PMF cases showed one or more of these features required for diagnosis… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
2 Citations
0 References
Similar Papers